BeOne Medicines

BeOne Medicines is a biotechnology company focused on developing oncology therapeutics. The company is best known for zanubrutinib (brand name: BRUKINSA), a next-generation BTK inhibitor approved by the FDA for multiple blood cancers including mantle cell lymphoma and Waldenström's macroglobulinemia. BRUKINSA is the company's primary commercial product and the main driver of its revenues.

BeOne Medicines is listed on NASDAQ under the ticker BGNE and on the Hong Kong Stock Exchange. The company is headquartered in San Mateo, California, with significant operations in China.

BeOne Medicines focuses on developing and commercializing cancer therapies, with an emphasis on hematological malignancies. Its lead product, zanubrutinib, competes directly with AbbVie/Janssen's ibrutinib and AstraZeneca's acalabrutinib in the BTK inhibitor category. The company conducted clinical trials demonstrating zanubrutinib's superiority over ibrutinib on certain efficacy and safety endpoints.

BRUKINSA (zanubrutinib) is the only product that has reached significant commercial launch. Additional pipeline candidates are in clinical development. BeOne Medicines has invested heavily in building independent manufacturing and research capabilities.

BeOne Medicines competes directly with AbbVie and AstraZeneca in the BTK inhibitor space. Clinical trial data showing BRUKINSA's comparative advantages has helped the company gain share in a market historically dominated by ibrutinib.

Detailed public information about any Israeli presence or Israeli operations for this company is not available.